Anti-VEGF drugs as initial treatment combined with ablation therapy are recommended to improve visual acuity in Coats’ disease, but the monitoring of fibrosis change and other adverse effects should be required (weak recommendation with very low certainty evidence). Here, VEGFA is linked to Coats disease.